The First Switched Time of PML/RARα Fusion Gene in Patients with Acute Promyelocytic Leukemia and Its Clinical Significance

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 23; no. 6; p. 1551
• Main Authors: Pu, Lian-Fang, Tao, Qian-Shan, Wang, Hui-Ping, Zhai, Zhi-Min, Xiong, Shu-Dao
• Format: Journal Article
• Language: Chinese
• Published: China 01.12.2015
• Subjects: Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prognosis; Recurrence; Remission Induction
• ISSN: 1009-2137
• DOI: 10.7534/j.issn.1009-2137.2015.06.004

To investigate the first switched time of PML/RARα fusion gene in patients with acute promyelocytic leukemia (APL) and its clinical significance. sixty cases of newly diagnosed APL were enrolled in this study. They received standard remission induction, consolidation and maintenance treatments according to the clinical pathway for APL, and were followed up. During the same time the PML/RARα fusion gene mRNA expression of all cases was detected by multi-nested PCR. except for 3 death cases and 1 case failed to follow-up, the PML/RARα fusion genes in the remaining 56 cases were firstly found to be negative from 24 to 381 days respectively, the mean value of the first switched time was 131 ± 90 days. There was no statistically significant difference in age, sex and risk stratification between different groups. However, the cases with L-type PML/RARα gene had shorter time compared with the patients with S-type PML/RARα gene (P = 0.032); then, for the above-mentimed 56 cases, the follow-up duration ranged from 25-